SOPHiA DDM™ Myeloid Solution

Expand the scope of myeloid neoplasms management

SOPHiA DDM™ Myeloid Solution is a ready-to-use genomic application, designed to empower clinical researchers to make better-informed decisions in the assessment of different blood cancer disorders.

This comprehensive solution accurately covers 30 genes associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. The application combines a capture-based target enrichment kit with the advanced analytical capabilities of the SOPHiA DDM™ platform, providing high-quality and reproducible data through a streamlined workflow from sample to report.

Ready-to-use target enriched library in just 2 days

Data analysis from FASTQ files in as little as 4 hours

Accurate detection and annotation of challenging variants, such as SNVs, Indels, CNVs, fusions, FLT3 internal tandem duplications in one unique experiment

Streamline interpretation with the SOPHiA DDM™ intuitive variant filters, algorithm-supported variant classification with OncoPortal™ to obtain the latest scientific evidence on all the relevant variants

Have access to one of the largest networks of connected healthcare institutions within SOPHiA DDM™, to gain and share knowledge on relevant variants

pink dots icon

Product Details

Confidently asses complex blood cancer variants

Molecular profiling by next-generation sequencing has introduced a paradigm shift in investigating the pathogenic variants causing different blood cancer disorders. Through a streamlined, customizable, and scalable NGS-based workflow, SOPHiA DDM™ Myeloid Solution reduces turnaround time and improves the efficiency of assessing complex variants associated with different blood cancers with uniform coverage of DNA alterations (e.g., CALR, CEBPA, ASXL1, FLT3, including internal tandem duplications) aligned with recent guidelines.

SOPHiA Myeloid Solution Screenshot
SOPHiA Myeloid Solution Shower Image

Dedicated features to ease variant interpretation

The SOPHiA DDM™ platform features intuitive variant filters and prioritization options to streamline the interpretation process and greatly reduce turnaround time.

  • Virtual Panels to limit the interpretation to a subset of genes
  • Cascading Filters to enable user-created custom filtering strategies for quicker identification of relevant variants
  • OncoPortal™ to support decisions based on the Jax-CKB™, CAP, ASCO, AMP and other data sources
workflow mobile image
icon quotes

“We were able to remove recurring artifacts and PCR errors. The solution correctly called Indels and large deletions, which were incorrectly identified by a previous pipeline, and we gained the ability to detect large insertions in FLT3 without using additional tools – this made the move a no-brainer.”

Olena Kis, PhD
Associate Director, Molecular Pathology

pink dots icon

Specifications

Parameters Myeloid Solution
Diseases Covered Myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia
Genes 30 genes (10 with complete coding sequences.) Panel:
ABL1, ASXL1, BRAF, CALR, CBL, CEBPA, CSF3R, DNMT3A, ETV6, EZH2, FLT3, HRAS, IDH1, IDH2, JAK2, KIT KRAS, MPL, NPM1, NRAS, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1, ZRSR2
Key Biomarkers CEBPA, ASXL1, CALR, FLT3 including internal tandem duplications
Target Region Size 48 Kb
Sample Type Blood and bone marrow
DNA Input Amount 50 ng DNA
Sequencer Compatibility
  • Illumina MiSeq® kit v3 (2x300bp)
  • Illumina MiSeq® kit v2 (2x250bp)
  • Illumina NextSeq® 500/500 Mid Output kit v2 (2x150bp)
  • Illumina NextSeq® 500/500 High Output kit v2 (2x150bp)
  • Ion Proton™ System Ion 540™ kit
Library Preparation Time 2 days
Analysis Time From FASTQ From 4 hours
Detected Variants
  • SNVs
  • Indels
  • CNVs
  • FLT3 internal tandem duplications
pink dots icon

Contact us

Please fill out the form below to get in touch

pink dots icon

Related products

SOPHiA DDM™ for Blood Cancers

Our future-proof end-to-end solutions allow detection and characterization of complex genomic variants associated with different blood cancers.

SOPHiA DDM™ For Blood Cancers

SOPHiA DDM™ for Solid Tumors

From targeted to comprehensive genomic profiling, our solutions support healthcare professionals in their journey to analyze solid tumors.

SOPHiA DDM™ For Solid Tumors

SOPHiA DDM™ for Hereditary Cancers

Our solutions help reduce time to confidently assess multiple types of challenging genetic variants that indicate predisposition to inherited cancers.

SOPHiA DDM™ For Hereditary Cancers
';